InsiderTrades

Form 4 for SABS SAB Biotherapeutics, Inc.

Accepted 2021-10-26 00:00:00 ET · period of report 2021-10-19 · accession 0001493152-21-026388 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2021-10-26 2021-10-19+ SABS Luke Thomas Charles Chief Medical Off A - Grant $10.10 +6,418 5,428 New +$64.8K
DM 2021-10-26 2021-10-22 SABS Luke Thomas Charles Chief Medical Off A - Grant — +214.5K 139.6K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-10-19 A A 990 $10.10 990 D — —
2 Common Common Stock 2021-10-22 A A 5,428 — 5,428 D — — (F1) Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each share of Old SAB Biotherapeutics issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").
3 Derivative Earnout Rights (Common Stock) 2021-10-22 A A 2,193 — 2,193 D — · — to — 2,193 Common Stock (F2) Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.] (F3) 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.
4 Derivative Earnout Rights (Restricted Stock Units) 2021-10-22 A A 61,092 — 61,092 D — · — to — 61,092 Common Stock (F6) In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares. (F5) The option is fully vested.
5 Derivative Employee Stock Option (right to buy) 2021-10-22 A A 11,632 — 11,632 D $1.25 · — to 2030-04-27 11,632 Common Stock (F5) The option is fully vested. (F4) Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.
6 Derivative Employee Stock Option (right to buy) 2021-10-22 A A 139,585 — 139,585 D $1.00 · — to 2028-10-01 139,585 Common Stock (F5) The option is fully vested. (F4) Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.